-
-
-
-
-
-
-
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
-
-
-
-
-
-
-
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
-
-
-
-
-
-
-
Takeda Pharmaceutical (TAK) and JCR Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
-
-
-
-
-
-
-
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
-
-
-
-
-
-
-
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Announces Strategic Partner Takeda (TAK) Exercises Option to Co-Develop and Co-Commercialize DNL593
-
-
-
-
-
-
-
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

